TrialFrontiers in endocrinology2023

Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial.

Zhijie Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.